{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=28",
    "query": {
      "condition": "Carcinoma, Non Small Cell Lung",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 3680,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T13:22:40.050Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00283634",
      "title": "A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "erlotinib and bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2005-08",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2011-02-17",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00283634"
    },
    {
      "nct_id": "NCT01456325",
      "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Squamous Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Onartuzumab (MetMab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 494,
      "start_date": "2012-01",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 56,
      "location_summary": "Chandler, Arizona • Hayward, California • Modesto, California + 47 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01456325"
    },
    {
      "nct_id": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Metastatic Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Small Cell Lung Cancer (SCLC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)"
      ],
      "interventions": [
        {
          "name": "Lomvastomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2018-10-15",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03708328"
    },
    {
      "nct_id": "NCT01752400",
      "title": "AUY922 for Advanced ALK-positive NSCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AUY922",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2013-01",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752400"
    },
    {
      "nct_id": "NCT04791215",
      "title": "Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-02-01",
      "completion_date": "2023-04-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04791215"
    },
    {
      "nct_id": "NCT05609578",
      "title": "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced NSCLC",
        "Metastatic Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Adagrasib oral dose of 400 mg twice daily tablets",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Chemotherapy: Pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin/Carboplatin",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2022-11-22",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 59,
      "location_summary": "Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609578"
    },
    {
      "nct_id": "NCT03452774",
      "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer, Metastatic",
        "Cancer",
        "Cancer of Pancreas",
        "Cancer of Liver",
        "Cancer of Stomach",
        "Cancer Liver",
        "Cancer of Rectum",
        "Cancer of Kidney",
        "Cancer of Esophagus",
        "Cancer of Cervix",
        "Cancer of Colon",
        "Cancer of Larynx",
        "Cancer, Lung",
        "Cancer, Breast",
        "Cancer, Advanced",
        "Cancer Prostate",
        "Cancer of Neck",
        "Cancer of Skin",
        "Neuroendocrine Tumors",
        "Carcinoma",
        "Mismatch Repair Deficiency",
        "BRCA Gene Rearrangement",
        "Non Hodgkin Lymphoma",
        "Leukemia",
        "Non Small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Glioblastoma",
        "Central Nervous System Tumor",
        "Melanoma",
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Testicular Cancer",
        "Breast Cancer",
        "COVID",
        "Myelofibrosis",
        "Myeloproliferative Neoplasm",
        "Myeloproliferative Disorders",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Clinical Trial Matching",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massive Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50000,
      "start_date": "2018-01-01",
      "completion_date": "2040-06",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452774"
    },
    {
      "nct_id": "NCT01820325",
      "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lunch Cancer"
      ],
      "interventions": [
        {
          "name": "Buparlisib",
          "type": "DRUG"
        },
        {
          "name": "Buparlisib placebo",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2013-09-09",
      "completion_date": "2014-06-18",
      "has_results": false,
      "last_update_posted_date": "2018-10-11",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 2,
      "location_summary": "Fayetteville, Arkansas • Portland, Oregon",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01820325"
    },
    {
      "nct_id": "NCT00003111",
      "title": "Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "1997-04",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2013-07-25",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003111"
    },
    {
      "nct_id": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2000-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-11-20T13:22:40.050Z",
      "location_count": 2,
      "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005842"
    }
  ]
}